Wu Yinying, Li Yi, Zhao Xiaoai, Dong Danfeng, Tang Chunhui, Li Enxiao, Geng Qianqian
Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Department of Geriatrics, Shaanxi Provincial People Hospital, Xi'an, Shaanxi 710068, P.R. China.
Oncol Lett. 2017 Jan;13(1):129-136. doi: 10.3892/ol.2016.5425. Epub 2016 Nov 23.
Molecular tumor markers hold considerable promise for accurately predicting the recurrence and progression of colorectal cancer (CRC) in patients. However, in the majority of cases, single marker analysis has been found to have low accuracy, and is of little practical use in clinical practice. The present study investigated the prognostic value of the combined detection of the protein expression of metastasis suppressor 23-H1 (Nm23-H1) and p53 using immunohistochemical analysis, and the mRNA expression levels were analyzed using reverse transcription-quantitative polymerase chain reaction in 110 cases of stage II and III CRC. The results revealed that the expression levels of Nm23-H1 in CRC tissues were lower, compared with those in normal tissues (χ=18.249; P<0.001), and the protein expression levels of p53 were higher in the CRC tissues (χ=23.940; P<0.001); although the mRNA expression levels of Nm23-H1 and p53 presented with the same trend. The protein expression of Nm23-H1 was correlated with lymph node metastases (χ=11.847; P=0.001) and pathological patterns (χ=6.911; P=0.032). However, it did not correlate with patient gender or age, or with tumor World Health Organization classification or invasive depth (P>0.05). No significant correlation was observed between the expression of p53 and clinicopathological features (P>0.05). Patients with CRC with Nm23-H1(+)/p53(-) tumors had increased survival rates, with a five-year overall survival rate of 83.8% and a five-year disease-free survival rate of 70.2%. The five-year overall survival rates in other study cohorts were lower, compared with the Nm23-H1(+)/p53(-) group (P<0.0125), and this was the same for the five-year disease-free survival rate (P<0.0125). In conclusion, the present study demonstrated that the combined detection of the protein expression of Nm23-H1 and p53 was associated with the long term survival rates of patients with stage II and III CRC; and this may offer potential for use as a predictor of survival rates in patients with CRC.
分子肿瘤标志物在准确预测结直肠癌（CRC）患者的复发和进展方面具有巨大潜力。然而，在大多数情况下，单一标志物分析的准确性较低，在临床实践中几乎没有实际用途。本研究采用免疫组织化学分析方法，探讨了转移抑制因子23-H1（Nm23-H1）和p53蛋白表达联合检测的预后价值，并采用逆转录定量聚合酶链反应分析了110例II期和III期CRC患者的mRNA表达水平。结果显示，与正常组织相比，CRC组织中Nm23-H1的表达水平较低（χ=18.249；P<0.001），而CRC组织中p53的蛋白表达水平较高（χ=23.940；P<0.001）；尽管Nm23-H1和p53的mRNA表达水平呈现相同趋势。Nm23-H1的蛋白表达与淋巴结转移（χ=11.847；P=0.001）和病理类型（χ=6.911；P=0.032）相关。然而，它与患者的性别、年龄、肿瘤世界卫生组织分类或浸润深度无关（P>0.05）。p53的表达与临床病理特征之间未观察到显著相关性（P>0.05）。患有Nm23-H1(+)/p53(-)肿瘤的CRC患者生存率提高，五年总生存率为83.8%，五年无病生存率为70.2%。与Nm23-H1(+)/p53(-)组相比，其他研究队列的五年总生存率较低（P<0.0125），五年无病生存率也是如此（P<0.0125）。总之，本研究表明，Nm23-H1和p53蛋白表达的联合检测与II期和III期CRC患者的长期生存率相关；这可能为CRC患者生存率的预测提供潜在依据。
Zotero 插件
